The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): A novel platform umbrella trial.
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicans' Education Resource; Research to Practice; Targeted Oncology
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Archer; AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; EMD Serono/Merck; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; Melendi; Monopteros Therapeutics; Monopteros Therapeutics; MORE Health; Novartis; Pfizer; Remedica; Repare Therapeutics; Takeda/Millennium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Haiying Liu
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Roche
 
Felice Wu
Employment - Roche/Genentech
 
David Chen
No Relationships to Disclose
 
Timothy Richard Wilson
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Brian P. Simmons
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Fabrice Barlesi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech